Article
Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia.
Blood - 9 Nov 2023
Senapati Jayastu, Urrutia Samuel, Loghavi Sanam, Short Nicholas J, Issa Ghayas C, Maiti Abhishek, Abbas Hussein A, Daver Naval G, Pemmaraju Naveen, Pierce Sherry, Chien Kelly S, Sasaki Koji, Kadia Tapan M, Hammond Danielle E, Borthakur Gautam, Patel Keyur, Ravandi Farhad, Kantarjian Hagop M, Garcia-Manero Guillermo, DiNardo Courtney D
Abstract excerpt
Mutations in splicing factor (SF) genes SRSF2, U2AF1, SF3B1, and ZRSR2 are now considered adverse risk in the European LeukemiaNet 2022 acute myeloid leukemia (AML) risk stratification. The prognostic impact of SF mutations in AML has been predominantly derived from younger patients treated with intensive (INT) therapy. We evaluated 994 patients with newly diagnosed AML, including 266 (27%) with a SFmut. Median...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.